Staff Reports
The Government Accountability Office has dropped a bomb on the Food and Drug Administration’s advisory-committee process. Its new report found the FDA is not transparent about how it decides conflicts of interest and appearance issues for advisory‑committee members and guest speakers. That finding, paired with a wrenching Senate hearing where rare‑disease families pleaded for help, has produced real fallout — including the departures of key FDA leaders — and put the agency squarely under bipartisan fire.
GAO report: Transparency or theater?
The GAO report (GAO‑26‑107877) is blunt: the FDA withdrew earlier guidance and now does not publicly explain how it determines whether advisory‑committee participants have conflicts or appearance problems. The auditors recommended the agency post clear guidance, publish timelines, and disclose key parts of its process so decisions aren’t made in the dark. HHS agreed with the recommendations, which is the bureaucratic version of admitting you’ve been hiding the ball.
Senate hearing pushed the issue — and families pushed back
Bipartisan outrage with real faces
The Senate Special Committee on Aging held a hearing called “From Regulator to Roadblock,” where families with children suffering from Duchenne, Huntington’s, Sanfilippo and other rare diseases testified about delays that cost lives. Chairman Rick Scott and Ranking Member Kirsten Gillibrand led a rare bipartisan rebuke. Lawmakers, patient groups and industry witnesses all pointed at the same problem: opaque committee rules, inconsistent standards, and requests for endless data that make small‑population trials nearly impossible.
Why this matters for rare‑disease patients
Advisory committees are supposed to advise. Instead, when they operate without clear rules and without meaningful patient voices, they delay therapies that can be life‑saving. Small‑population research can’t be judged the same way as large, long trials for common diseases. Patients and advocates have been pushing for disease‑specific experts on panels, mandated patient representation, and acceptance of real‑world evidence — sensible fixes the GAO findings now give Congress and the next FDA commissioner cover to demand.
What to watch next
The GAO recommendations are simple and implementable: publish the rules, set timelines, and make waiver and recusal processes visible. Expect more congressional oversight, follow‑up reports, and possible legislative fixes if the agency stalls. The recent exits of Vinay Prasad from CBER and Commissioner Marty Makary show the political pressure is real — but leadership churn alone won’t help patients. The next FDA leadership should stop treating transparency like an optional extra and start treating timely patient access like the emergency it is. Otherwise, bureaucratic “no” will keep costing lives while politicians and pundits clap each other on the back.
